AstraZeneca PLC Ordinary Shares (AZN)
AZN moved a median of +0.03% 30 minutes after news, and -0.07% by the close. How AZN actually reacts to news — the realized, point-in-time move the market made, measured across 1,632 labeled events over the last three years with zero look-ahead.
AZN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 1,619 |
| 30-min | +0.03% | 54% | 1,629 |
| 60-min | +0.08% | 57% | 1,629 |
| to close | -0.07% | 45% | 1,624 |
| Middle 50% of AZN reactions | -0.20% to +0.27% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 1,632 |
Half of all AstraZeneca PLC Ordinary Shares news events land between -0.20% and +0.27% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AZN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 25 | +0.12% | 56% | -0.27% |
| Analyst downgrades | 16 | +0.33% | 75% | +0.48% |
| Coverage initiations | 22 | +0.10% | 64% | +0.68% |
| Rating reiterations | 35 | +0.04% | 57% | -0.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how AZN ranks against every other measured name →
That’s how AZN usually reacts — get an email when it moves on news →Email me when AZN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AZN's baseline. Nothing else.
Recent AZN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts | Press release | Business Wire | -0.01% | +0.57% | |
| Form 6-K ASTRAZENECA PLC For: Oct 05 | SEC filing · Form 6-K | SEC EDGAR | +0.02% | -0.12% | |
| Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types | Press release | Business Wire | -0.44% | -0.98% | |
| Form 6-K ASTRAZENECA PLC For: Oct 02 | SEC filing · Form 6-K | SEC EDGAR | -0.44% | -0.98% | |
| Form 6-K ASTRAZENECA PLC For: Oct 01 | SEC filing · Form 6-K | SEC EDGAR | +0.13% | -0.80% | |
| Form 6-K ASTRAZENECA PLC For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | +0.56% | -0.52% | |
| Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer | Press release | Business Wire | -0.16% | +0.32% | |
| Form 6-K ASTRAZENECA PLC For: Sep 23 | SEC filing · Form 6-K | SEC EDGAR | +0.46% | -2.00% | |
| Form 6-K ASTRAZENECA PLC For: Sep 21 | SEC filing · Form 6-K | SEC EDGAR | -0.14% | -0.15% | |
| Form 6-K ASTRAZENECA PLC For: Sep 18 | SEC filing · Form 6-K | SEC EDGAR | +0.39% | -0.59% | |
| Form 6-K ASTRAZENECA PLC For: Sep 15 | SEC filing · Form 6-K | SEC EDGAR | +0.12% | +0.11% | |
| Form 6-K ASTRAZENECA PLC For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | -0.13% | -0.13% | |
| ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial | Press release | Business Wire | -0.13% | -0.13% | |
| TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial | Press release | Business Wire | -0.13% | -0.13% | |
| Form 6-K ASTRAZENECA PLC For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | -0.60% | -2.39% | |
| IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer | Press release | Business Wire | -0.60% | -2.39% | |
| Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials | Press release | Business Wire | -0.60% | -2.39% | |
| ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer | Press release | Business Wire | -0.60% | -2.39% | |
| AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer | Press release | Business Wire | -0.18% | -0.83% | |
| Form 6-K ASTRAZENECA PLC For: Sep 01 | SEC filing · Form 6-K | SEC EDGAR | -0.18% | -0.83% | |
| Form 6-K ASTRAZENECA PLC For: Aug 27 | SEC filing · Form 6-K | SEC EDGAR | +0.16% | -0.45% | |
| TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints | Press release | Business Wire | +0.16% | -0.45% | |
| Form 6-K ASTRAZENECA PLC For: Aug 25 | SEC filing · Form 6-K | SEC EDGAR | +0.10% | +1.66% | |
| Form 6-K ASTRAZENECA PLC For: Aug 19 | SEC filing · Form 6-K | SEC EDGAR | +0.30% | +0.66% | |
| ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial | Press release | Business Wire | +0.36% | +0.39% | |
| Form 6-K ASTRAZENECA PLC For: Aug 17 | SEC filing · Form 6-K | SEC EDGAR | +0.36% | +0.39% | |
| TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO | Press release | Business Wire | +0.36% | +0.39% | |
| Form 6-K ASTRAZENECA PLC For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | +0.21% | +1.57% | |
| Form 6-K ASTRAZENECA PLC For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | -0.61% | -0.52% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bronstein, Gewirtz & Grossman, LLC (AZN) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.24% | -0.10% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AstraZeneca PLC (AZN) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.23% | -0.13% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AstraZeneca PLC (AZN) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.38% | -0.41% | |
| AstraZeneca results: H1 and Q2 2026 | Press release | Business Wire | -0.31% | -0.15% | |
| Form 6-K ASTRAZENECA PLC For: Jul 27 | SEC filing · Form 6-K | SEC EDGAR | -0.31% | -0.15% | |
| Form 6-K ASTRAZENECA PLC For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.31% | -0.15% | |
| Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers | Press release | Business Wire | -0.31% | -0.15% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.31% | -0.15% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.26% | -0.32% | |
| Form 6-K ASTRAZENECA PLC For: Jul 23 | SEC filing · Form 6-K | SEC EDGAR | +0.92% | +1.14% | |
| AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.10% | +2.01% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.13% | -2.17% | |
| AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.16% | -0.60% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AstraZeneca PLC (AZN) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.26% | -0.04% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.04% | -0.06% | |
| Form 6-K ASTRAZENECA PLC For: Jul 14 | SEC filing · Form 6-K | SEC EDGAR | -0.06% | -1.71% | |
| Form 6-K ASTRAZENECA PLC For: Jul 09 | SEC filing · Form 6-K | SEC EDGAR | +0.64% | +3.21% | |
| Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC | Press release | PR Newswire | +0.16% | +3.08% | |
| Form 6-K ASTRAZENECA PLC For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | +0.08% | -0.02% | |
| Form 11-K ASTRAZENECA PLC For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | -0.04% | +0.41% | |
| Form 6-K ASTRAZENECA PLC For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | -0.30% | +0.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AZN section they belong to.
Where else AZN is measured.
AZN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MYLAN NV ORDINARY SHARES (MYL) | 1,701 | -0.13% | 44% |
| Inspire Medical Systems, Inc. (INSP) | 1,692 | +0.06% | 53% |
| Alexion Pharmaceuticals, Inc (ALXN) | 1,615 | -0.04% | 49% |
| ADMA Biologics Inc (ADMA) | 1,609 | +0.11% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AstraZeneca PLC Ordinary Shares's median reaction calculated?
Every labeled AZN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,632 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of AZN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AZN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.